Julian Gangolli

Director at Outlook Therapeutics.

Iselin, NJ
Outlook Therapeutics

Raised on Outlook Therapeutics filings

No sales reported yet

of $37M offered across 2 Form D filings

Form D filings: 2
Teammates: 1
Last filing: May 7, 2026

Company

Outlook Therapeutics

Biotech · Iselin, NJ

Ophthalmic bevacizumab for wet macular degeneration

Ophthalmic bevacizumab for wet macular degeneration

Investors: 10
Still open: $37M

Investors: 10
Sector: Biotech
HQ: Iselin, NJ

Outlook Therapeutics filings

Outlook Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
May 7, 2026	Equity	None sold/ $5M	Form D
Jan 27, 2025	Equity	None sold/ $32M	Form D

EquityFiled May 7, 2026Form D
None sold/ $5M
EquityFiled Jan 27, 2025Form D
None sold/ $32M

Works with

Also named on Outlook Therapeutics filings

Lawrence KenyonInterim Chief Executive Officer, CFO, Treas & Sec'y, Form D signerForm D signer